Tyrosine kinase inhibitor (TKIs)

DRUG2 trials

Conditions

Allogeneic Hematopoietic Stem Cell TransplantationHepatic Arterial Infusion ChemotherapyHepatocellular Carcinoma (HCC)Immune Checkpoint InhibitorsMinimal Residual DiseasePhiladelphia Chromosome Positive Acute Lymphocytic LeukemiaTyrosine Kinase Inhibitor

Phase 2

Effect of Prophylactic TKI Therapy Post-transplants on Ph+ ALL Undergoing Allo-HSCT With MRD Positive Pre-transplants

NCT03624530

Nanfang Hospital, Southern Medical UniversityPhiladelphia Chromosome Positive Acute Lymphocytic Leukemia, Tyrosine Kinase Inhibitor, Minimal Residual Disease +1

Start: 2018-08-31End: 2022-07-31Target: 82Updated: 2018-08-10

Unknown Phase

HAIC in Combination with Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Advanced HCC

Active, not recruitingNCT06632106

First Hospital of China Medical UniversityHepatic Arterial Infusion Chemotherapy, Tyrosine Kinase Inhibitor, Immune Checkpoint Inhibitors +1

Start: 2024-08-16End: 2025-05-30Updated: 2024-10-08

Tyrosine kinase inhibitor (TKIs)

Sponsors

Conditions

Phase 2

Unknown Phase